Abstract
BackgroundCs2K4Na [SiW9Nb3O40] (POM93) is a novel broad-spectrum antiviral agent with high activity, high stability, and low toxicity in vitro. Most toxicity studies for POM93 have been performed in cultured cell lines rather than in animals. Like other POMs, there is a lack of evidence for in vivo toxicity limits, oral bioavailability, and therapeutic applications.MethodsThe toxic properties of POM93 were evaluated comprehensively in vivo, including the acute and subchronic oral toxicity studies and genotoxicity tests.ResultsThe acute toxicity study showed no abnormal changes or mortality in rats treated with POM93 even at the single high dose of 5000 mg/kg body weight. In the subchronic toxicity study, regardless of the body weight, the organ weight, and the hematological parameters, similar results were observed between the control group and the experimental groups. POM93 produced mild changes in rare hematological parameters in the liver and kidneys, but did not induce the clinical symptoms of liver or kidneys injury in rats as confirmed by histopathological analysis. Moreover, neither mutagenicity nor clastogenicity was caused by POM93 treatment in vitro and in vivo.ConclusionsThe present study demonstrates that the oral administration of POM93 is presumed safe and poses a low risk of potential health risks.
Highlights
Cs2K4Na [SiW9Nb3O40] (POM93) is a novel broad-spectrum antiviral agent with high activity, high stability, and low toxicity in vitro
POM with the formula of Cs2K4Na[SiW9Nb3O40] (POM93) treatment caused neither mutagenicity nor clastogenicity in vitro and in vivo Mutagenicity of the POM93 was evaluated in a bacterial reverse mutation assay in four Histidine-requiring strains of S. typhimurium (TA97, TA98, TA100, and TA102)
The micronucleus assay test revealed that POM93 did not induce numerical or structural chromosomal damage at the administered levels, with no acute toxicity being observed in the groups. These data indicated that neither mutagenicity nor clastogenicity was caused by POM93 treatments
Summary
Cs2K4Na [SiW9Nb3O40] (POM93) is a novel broad-spectrum antiviral agent with high activity, high stability, and low toxicity in vitro. Qu et al BMC Pharmacology and Toxicology (2017) 18:26 reduced POM toxicity through discovering of new POMs [12], such as encapsulating POMs in biomaterials (such as zeolites and biodegradable/biocompatible hydrogels) [13, 14], and conjugating POMs with organic ligands [15]. These strategies improve POMs’ biocompatibility [16], allow selective recognition of biological targets [17], and tune the bioactivity and cytotoxicity of POMs [18, 19]. Investigation of acute and subchronic toxicity is essential before the development of POMs for clinical trials, because of the mechanism and consequence of toxicity in vivo was different from that of in vitro
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
